1. Home
  2. APRE vs EPWK Comparison

APRE vs EPWK Comparison

Compare APRE & EPWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APRE
  • EPWK
  • Stock Information
  • Founded
  • APRE 2006
  • EPWK 2011
  • Country
  • APRE United States
  • EPWK China
  • Employees
  • APRE N/A
  • EPWK N/A
  • Industry
  • APRE Biotechnology: Biological Products (No Diagnostic Substances)
  • EPWK
  • Sector
  • APRE Health Care
  • EPWK
  • Exchange
  • APRE Nasdaq
  • EPWK Nasdaq
  • Market Cap
  • APRE 10.0M
  • EPWK 11.0M
  • IPO Year
  • APRE 2019
  • EPWK 2025
  • Fundamental
  • Price
  • APRE $1.80
  • EPWK $0.52
  • Analyst Decision
  • APRE Strong Buy
  • EPWK
  • Analyst Count
  • APRE 2
  • EPWK 0
  • Target Price
  • APRE $15.50
  • EPWK N/A
  • AVG Volume (30 Days)
  • APRE 50.9K
  • EPWK 3.1M
  • Earning Date
  • APRE 08-11-2025
  • EPWK 05-27-2025
  • Dividend Yield
  • APRE N/A
  • EPWK N/A
  • EPS Growth
  • APRE N/A
  • EPWK N/A
  • EPS
  • APRE N/A
  • EPWK N/A
  • Revenue
  • APRE $1,284,475.00
  • EPWK $20,164,008.00
  • Revenue This Year
  • APRE N/A
  • EPWK N/A
  • Revenue Next Year
  • APRE N/A
  • EPWK N/A
  • P/E Ratio
  • APRE N/A
  • EPWK N/A
  • Revenue Growth
  • APRE 33.27
  • EPWK 10.25
  • 52 Week Low
  • APRE $1.41
  • EPWK $0.41
  • 52 Week High
  • APRE $5.01
  • EPWK $26.00
  • Technical
  • Relative Strength Index (RSI)
  • APRE 49.58
  • EPWK N/A
  • Support Level
  • APRE $1.64
  • EPWK N/A
  • Resistance Level
  • APRE $1.81
  • EPWK N/A
  • Average True Range (ATR)
  • APRE 0.15
  • EPWK 0.00
  • MACD
  • APRE -0.01
  • EPWK 0.00
  • Stochastic Oscillator
  • APRE 51.76
  • EPWK 0.00

About APRE Aprea Therapeutics Inc. Common stock

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

About EPWK EPWK Holdings Ltd. Class A Ordinary Shares

EPWK Holdings Ltd create an innovative and efficient crowdsourcing platform to connect businesses with great talents. It operates online marketplace to enable businesses (buyers) and service providers (sellers) to find each other. The platform users consist of buyers who seek talents for their jobs and sellers who offer different talents and skills. The company derives revenue mainly comes from providing various value-added services for users on both supply and demand sides.

Share on Social Networks: